TWI845482B - 用於抑制類polo激酶4之組合療法 - Google Patents

用於抑制類polo激酶4之組合療法 Download PDF

Info

Publication number
TWI845482B
TWI845482B TW107131410A TW107131410A TWI845482B TW I845482 B TWI845482 B TW I845482B TW 107131410 A TW107131410 A TW 107131410A TW 107131410 A TW107131410 A TW 107131410A TW I845482 B TWI845482 B TW I845482B
Authority
TW
Taiwan
Prior art keywords
cancer
antibody
pharmaceutically acceptable
inhibitor
cfi
Prior art date
Application number
TW107131410A
Other languages
English (en)
Chinese (zh)
Other versions
TW201919637A (zh
Inventor
賈桂林 Ｍ 曼森
馬克 Ｒ 布雷
塔克 瓦 馬柯
葛漢 佛勒雀
Original Assignee
加拿大健康網路大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大健康網路大學 filed Critical 加拿大健康網路大學
Publication of TW201919637A publication Critical patent/TW201919637A/zh
Application granted granted Critical
Publication of TWI845482B publication Critical patent/TWI845482B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW107131410A 2017-09-08 2018-09-07 用於抑制類polo激酶4之組合療法 TWI845482B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555718P 2017-09-08 2017-09-08
US62/555,718 2017-09-08

Publications (2)

Publication Number Publication Date
TW201919637A TW201919637A (zh) 2019-06-01
TWI845482B true TWI845482B (zh) 2024-06-21

Family

ID=65633360

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107131410A TWI845482B (zh) 2017-09-08 2018-09-07 用於抑制類polo激酶4之組合療法

Country Status (8)

Country Link
US (1) US12109215B2 (https=)
EP (1) EP3678669A4 (https=)
JP (2) JP7343483B2 (https=)
CN (1) CN111225670A (https=)
AU (2) AU2018328773B2 (https=)
CA (1) CA3074876A1 (https=)
TW (1) TWI845482B (https=)
WO (1) WO2019046949A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
JP2023505301A (ja) * 2019-12-06 2023-02-08 ユニバーシティー ヘルス ネットワーク 急性骨髄性白血病または骨髄異形成症候群に対する治療
US20230165871A1 (en) * 2020-04-06 2023-06-01 University Health Network Combination therapies for inhibition of polo-like kinase 4
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.
WO2022266240A1 (en) * 2021-06-16 2022-12-22 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442906B2 (ja) * 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US8933070B2 (en) * 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
RS58413B1 (sr) * 2013-10-18 2019-04-30 Univ Health Network So i kristalni oblici inhibitora plk-4
SG11201602882VA (en) * 2013-10-18 2016-05-30 Univ Health Network Treatment for pancreatic cancer
ES2686549T3 (es) * 2014-06-16 2018-10-18 Worldwide Innovative Network Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
EP3981430A1 (en) * 2015-01-21 2022-04-13 Memorial Sloan Kettering Cancer Center Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells
AU2016219204B2 (en) * 2015-02-12 2021-01-21 Beyondspring Pharmaceuticals, Inc. Use of Plinabulin in combination with immune checkpoint inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 2017年04月13日，The Summit for Cancer Immunotherapy (Summit4CI), June，26–29, 2016 Halifax, Canada，Cancer Immunol Immunother (2017) 66:811–818

Also Published As

Publication number Publication date
WO2019046949A1 (en) 2019-03-14
AU2018328773B2 (en) 2023-11-16
JP2020533293A (ja) 2020-11-19
US20210060026A1 (en) 2021-03-04
US12109215B2 (en) 2024-10-08
JP7343483B2 (ja) 2023-09-12
EP3678669A4 (en) 2021-06-09
TW201919637A (zh) 2019-06-01
EP3678669A1 (en) 2020-07-15
CN111225670A (zh) 2020-06-02
AU2018328773A1 (en) 2020-03-26
AU2024200937A1 (en) 2024-02-29
CA3074876A1 (en) 2019-03-14
JP2023155459A (ja) 2023-10-20

Similar Documents

Publication Publication Date Title
AU2022200196B2 (en) Methods, compositions, and kits for treatment of cancer
TWI845482B (zh) 用於抑制類polo激酶4之組合療法
CN107743401B (zh) 包含抗pd-1抗体和另外的抗体的组合的组合物
KR102333658B1 (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
CN115350263A (zh) 谷氨酸调节剂与免疫疗法用以治疗癌症的用途
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
US20230390294A1 (en) Combination therapies for inhibition of ttk protein kinase
TW202038942A (zh) 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
US12419890B2 (en) Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
CN113164599B (zh) 抗pd-l1单克隆抗体治疗癌症的用途

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees